Israeli MDMA therapy trial reports major PTSD relief for 80% of soldiers
MDMA-assisted psychotherapy lacks formal medical approval in Israel and the United States, remaining restricted strictly to authorized clinical trial environments.
MDMA-assisted psychotherapy lacks formal medical approval in Israel and the United States, remaining restricted strictly to authorized clinical trial environments.
It allocates an annual budget of NIS 450 million ($120 million) specifically for mental health services, ensuring that every soldier receives a personalized treatment plan within 72 hours of discharge.
Since Oct. 7, thousands of IDF soldiers have been impacted by the horrors of war, with many struggling to regain normalcy after leaving the battlefield, as Israel’s medical and psychological experts work to keep up.
Alon’s wife fainted, but his mother insisted, “Do everything possible.”
The Rehabilitation Division reported in March that Israel faces 100,000 disabled veterans by 2030 with half suffering psychological conditions.
Nearly half of the 16,500 injured soldiers processed by the Rehabilitation Department since the war began are being treated for PTSD.
The early days of the war were fueled by intense motivation, but a shift to defensive tasks last January dulled the sense of purpose.
PTSD is not limited to soldiers, says a Ben-Gurion University study released in March that found that nearly half of young Israelis showed symptoms of war-related PTSD.
Yishai Greenbaum lived a life shaped by service, love, and unwavering commitment to others.
‘As a husband and father of two, I knew that I needed to get the treatment I needed before life spiraled out of control.’
Combat veteran hospitalized in life-threatening condition; his mother says she and her son were repeatedly ignored by the Defense Ministry.
Post-Traumatic Stress Disorder (PTSD) is a pressing issue affecting many military personnel, including the brave men and women serving in the Israeli Defense Forces (IDF).
